{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:57Z","timestamp":1793215137513,"version":"4.5.0"},"reference-count":70,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["32070764"],"award-info":[{"award-number":["32070764"]}]},{"name":"National Natural Science Foundation of China","award":["81800087"],"award-info":[{"award-number":["81800087"]}]},{"name":"National Natural Science Foundation of China","award":["ZYJC18021"],"award-info":[{"award-number":["ZYJC18021"]}]},{"name":"National Natural Science Foundation of China","award":["ZYJC21023"],"award-info":[{"award-number":["ZYJC21023"]}]},{"name":"National Natural Science Foundation of China","award":["2021YFQ0030"],"award-info":[{"award-number":["2021YFQ0030"]}]},{"name":"National Natural Science Foundation of China","award":["2020YFH0073"],"award-info":[{"award-number":["2020YFH0073"]}]},{"name":"National Natural Science Foundation of China","award":["2021YFG0329"],"award-info":[{"award-number":["2021YFG0329"]}]},{"name":"National Natural Science Foundation of China","award":["2020HXBH139"],"award-info":[{"award-number":["2020HXBH139"]}]},{"name":"National Natural Science Foundation of China","award":["2021HXBH074"],"award-info":[{"award-number":["2021HXBH074"]}]},{"name":"National Natural Science Foundation of China","award":["2021-JCJQ-JJ-0533"],"award-info":[{"award-number":["2021-JCJQ-JJ-0533"]}]},{"name":"West China Hospital, Sichuan University","award":["32070764"],"award-info":[{"award-number":["32070764"]}]},{"name":"West China Hospital, Sichuan University","award":["81800087"],"award-info":[{"award-number":["81800087"]}]},{"name":"West China Hospital, Sichuan University","award":["ZYJC18021"],"award-info":[{"award-number":["ZYJC18021"]}]},{"name":"West China Hospital, Sichuan University","award":["ZYJC21023"],"award-info":[{"award-number":["ZYJC21023"]}]},{"name":"West China Hospital, Sichuan University","award":["2021YFQ0030"],"award-info":[{"award-number":["2021YFQ0030"]}]},{"name":"West China Hospital, Sichuan University","award":["2020YFH0073"],"award-info":[{"award-number":["2020YFH0073"]}]},{"name":"West China Hospital, Sichuan University","award":["2021YFG0329"],"award-info":[{"award-number":["2021YFG0329"]}]},{"name":"West China Hospital, Sichuan University","award":["2020HXBH139"],"award-info":[{"award-number":["2020HXBH139"]}]},{"name":"West China Hospital, Sichuan University","award":["2021HXBH074"],"award-info":[{"award-number":["2021HXBH074"]}]},{"name":"West China Hospital, Sichuan University","award":["2021-JCJQ-JJ-0533"],"award-info":[{"award-number":["2021-JCJQ-JJ-0533"]}]},{"name":"Sichuan Science and Technology Program","award":["32070764"],"award-info":[{"award-number":["32070764"]}]},{"name":"Sichuan Science and Technology Program","award":["81800087"],"award-info":[{"award-number":["81800087"]}]},{"name":"Sichuan Science and Technology Program","award":["ZYJC18021"],"award-info":[{"award-number":["ZYJC18021"]}]},{"name":"Sichuan Science and Technology Program","award":["ZYJC21023"],"award-info":[{"award-number":["ZYJC21023"]}]},{"name":"Sichuan Science and Technology Program","award":["2021YFQ0030"],"award-info":[{"award-number":["2021YFQ0030"]}]},{"name":"Sichuan Science and Technology Program","award":["2020YFH0073"],"award-info":[{"award-number":["2020YFH0073"]}]},{"name":"Sichuan Science and Technology Program","award":["2021YFG0329"],"award-info":[{"award-number":["2021YFG0329"]}]},{"name":"Sichuan Science and Technology Program","award":["2020HXBH139"],"award-info":[{"award-number":["2020HXBH139"]}]},{"name":"Sichuan Science and Technology Program","award":["2021HXBH074"],"award-info":[{"award-number":["2021HXBH074"]}]},{"name":"Sichuan Science and Technology Program","award":["2021-JCJQ-JJ-0533"],"award-info":[{"award-number":["2021-JCJQ-JJ-0533"]}]},{"name":"West China Hospital","award":["32070764"],"award-info":[{"award-number":["32070764"]}]},{"name":"West China Hospital","award":["81800087"],"award-info":[{"award-number":["81800087"]}]},{"name":"West China Hospital","award":["ZYJC18021"],"award-info":[{"award-number":["ZYJC18021"]}]},{"name":"West China Hospital","award":["ZYJC21023"],"award-info":[{"award-number":["ZYJC21023"]}]},{"name":"West China Hospital","award":["2021YFQ0030"],"award-info":[{"award-number":["2021YFQ0030"]}]},{"name":"West China Hospital","award":["2020YFH0073"],"award-info":[{"award-number":["2020YFH0073"]}]},{"name":"West China Hospital","award":["2021YFG0329"],"award-info":[{"award-number":["2021YFG0329"]}]},{"name":"West China Hospital","award":["2020HXBH139"],"award-info":[{"award-number":["2020HXBH139"]}]},{"name":"West China Hospital","award":["2021HXBH074"],"award-info":[{"award-number":["2021HXBH074"]}]},{"name":"West China Hospital","award":["2021-JCJQ-JJ-0533"],"award-info":[{"award-number":["2021-JCJQ-JJ-0533"]}]},{"name":"National Defens Program of Technology","award":["32070764"],"award-info":[{"award-number":["32070764"]}]},{"name":"National Defens Program of Technology","award":["81800087"],"award-info":[{"award-number":["81800087"]}]},{"name":"National Defens Program of Technology","award":["ZYJC18021"],"award-info":[{"award-number":["ZYJC18021"]}]},{"name":"National Defens Program of Technology","award":["ZYJC21023"],"award-info":[{"award-number":["ZYJC21023"]}]},{"name":"National Defens Program of Technology","award":["2021YFQ0030"],"award-info":[{"award-number":["2021YFQ0030"]}]},{"name":"National Defens Program of Technology","award":["2020YFH0073"],"award-info":[{"award-number":["2020YFH0073"]}]},{"name":"National Defens Program of Technology","award":["2021YFG0329"],"award-info":[{"award-number":["2021YFG0329"]}]},{"name":"National Defens Program of Technology","award":["2020HXBH139"],"award-info":[{"award-number":["2020HXBH139"]}]},{"name":"National Defens Program of Technology","award":["2021HXBH074"],"award-info":[{"award-number":["2021HXBH074"]}]},{"name":"National Defens Program of Technology","award":["2021-JCJQ-JJ-0533"],"award-info":[{"award-number":["2021-JCJQ-JJ-0533"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: More and more trials have been conducted. We aimed to assess the efficacy and safety of different JAKinibs in RA. Methods: A systematic search of randomized controlled trials (RCTs) with JAKinib treatment in RA published in the Medline, Embase, and Cochrane databases up to May 2021 was performed. Results: 37 trials involving 15,174 patients were identified. Pooled analysis revealed that JAKinibs were associated with significant therapeutic improvement in RA patients as determined by ACR20 (RR = 2.03, 95% CI: 1.85 to 2.28) and HAQ-DI (MD = \u22120.31, 95% CI: \u22120.33 to \u22120.28) over placebo. Compared to placebo, JAKinib treatment was also associated with more adverse events (RR = 1.10, p &lt; 0.001; RR = 1.29, p &lt; 0.001; RR = 1.59, p = 0.02). Baricitinib and upadacitinib were related to more frequent adverse events (RR = 1.10; 95% CI: 1.01, 1.21; RR = 1.19; 95% CI: 1.11, 1.28) and infection (RR = 1.22; 95% CI: 1.09, 1.37; RR = 1.38; 95% CI: 1.22, 1.56), whereas only baricitinib was associated with more herpes zoster (RR = 3.15; 95% CI: 1.19, 8.33). Conclusions: JAKinibs were superior to placebo for improving signs, symptoms, and health-related quality of life in RA patients at short term, whereas the overall risk of adverse events and infections were greater with baricitinib and upadacitinib, and a higher risk of herpes zoster was only associated with baricitinib. More trials are needed to investigate the long-term safety.<\/jats:p>","DOI":"10.3390\/jcm11154459","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T02:06:42Z","timestamp":1659319602000},"page":"4459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis"],"prefix":"10.3390","volume":"11","author":[{"given":"Faping","family":"Wang","sequence":"first","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoju","family":"Tang","sequence":"additional","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Mao","sequence":"additional","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Wan","sequence":"additional","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-3437","authenticated-orcid":false,"given":"Fengming","family":"Luo","sequence":"additional","affiliation":[{"name":"Laboratory of Pulmonary Immunology and Inflammation, Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid Arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13543784.2016.1249565","article-title":"Developments with investigational Janus kinase inhibitors for rheumatoid arthritis","volume":"25","author":"Semerano","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: From biological agents to small molecules","volume":"18","author":"Ceribelli","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: First Approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","article-title":"The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: A systematic review and meta-analysis","volume":"32","author":"Kawalec","year":"2013","journal-title":"Clin Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Botella","year":"2006","journal-title":"Psychol. Methods."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis. Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis. Care Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1109071","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"Tanaka","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: Results from a randomised controlled trial","volume":"17","author":"Kremer","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: Results from a phase 3 study","volume":"38","author":"Li","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): A placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1136\/annrheumdis-2015-208901","article-title":"Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Clinical and MRI findings","volume":"75","author":"Genovese","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: A randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_56","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_57","unstructured":"U.S. Food and Drug Administration (2021, May 25). Full Prescribing Information for XELJANZ (tofacitinib). May 2018, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf."},{"key":"ref_58","unstructured":"U.S. Food and Drug Administration (2021, May 25). Full Prescribing Information for OLUMIANT (baricitinib). May 2018, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf."},{"key":"ref_59","unstructured":"Administration UFaD (2021, May 25). Full Prescribing Information for RINVOQ\u2122 (upadacitinib) 2019. August 2019, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00393-018-0531-5","article-title":"Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials","volume":"78","author":"Bae","year":"2019","journal-title":"Z. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_63","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: The patient\u2019s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-018-4199-7","article-title":"Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: A systematic literature review and meta-analysis of randomized controlled trials","volume":"37","author":"Kunwar","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo. Clin. Proc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:10Z","timestamp":1760140810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":70,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11154459"],"URL":"https:\/\/doi.org\/10.3390\/jcm11154459","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]}}}